Treatment with high dose of erythropoiesis‐stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 1053-8569, Iss. 10, 2015-10 ,pp. : 1068-1075

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of Anaemia with Erythropoiesis-Stimulating Agents in Patients with Chronic Kidney Disease Does Not Lower Mortality and May Increase Cardiovascular Risk: A Meta-Analysis

By  

Nephron Clin Pract, Vol. 121, Iss. 3-4, 2012-11 ,pp. : c95-c101

Karger

Access to resources Recommend Favorite

Use and cost of erythropoiesis-stimulating agents in patients with cancer

By Daniel Gregory   Hurley Dana   Whyte Joanna L.   Willey Vincent   Wilson Marcus   Kallich Joel  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1775-1784

Informa Healthcare

Access to resources Recommend Favorite

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents*

By Silver M. R.   Geronemus R.   Krause M.   Chen C. Y.   Kewalramani R.   Stehman-Breen C.  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 123-131

Informa Healthcare

Access to resources Recommend Favorite

Treatment of renal anaemia with erythropoiesis‐stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis

By  

NEPHROLOGY, Vol. 20, Iss. S4, 2015-12 ,pp. : 29-32

John Wiley & Sons Inc

Access to resources Recommend Favorite